{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T16:47:40Z","timestamp":1776185260826,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,2]]},"DOI":"10.7759\/cureus.41287","type":"journal-article","created":{"date-parts":[[2023,7,2]],"date-time":"2023-07-02T21:31:41Z","timestamp":1688333501000},"source":"Crossref","is-referenced-by-count":6,"title":["Cancer Therapy-Related Cardiotoxicity: A Comprehensive Retrospective Analysis at Najran Cancer Center, Saudi Arabia"],"prefix":"10.7759","author":[{"given":"Ahmed M","family":"Badheeb","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faisal","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hassan A","family":"Alzahrani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed  A","family":"Badheeb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamoud  Y","family":"Obied","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Islam  A","family":"Seada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Adriamycin (doxorubicin) cardiotoxicity: a review","volume":"131","author":"Chlebowski RT","year":"1979","unstructured":"Chlebowski RT. Adriamycin (doxorubicin) cardiotoxicity: a review. West J Med. 1979, 131:364-8.","journal-title":"West J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S313874","article-title":"Cardiotoxicity and cardiac monitoring among anthracycline-treated cancer patients: a retrospective cohort study","volume":"13","author":"Alkofide H","year":"2021","unstructured":"Alkofide H, Alnaim L, Alorf N, Alessa W, Bawazeer G. Cardiotoxicity and cardiac monitoring among anthracycline-treated cancer patients: a retrospective cohort study. Cancer Manag Res. 2021, 13:5149-59. 10.2147\/CMAR.S313874","journal-title":"Cancer Manag Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/ph14100970","article-title":"Anticancer drug-induced cardiotoxicity: insights and pharmacogenetics","volume":"14","author":"Adhikari A","year":"2021","unstructured":"Adhikari A, Asdaq SM, Al Hawaj MA, et al.. Anticancer drug-induced cardiotoxicity: insights and pharmacogenetics. Pharmaceuticals (Basel). 2021, 14:970. 10.3390\/ph14100970","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1177\/1179546819866445","article-title":"Cancer therapy-related cardiac dysfunction: an overview for the clinician","volume":"13","author":"Perez IE","year":"2019","unstructured":"Perez IE, Taveras Alam S, Hernandez GA, Sancassani R. Cancer therapy-related cardiac dysfunction: an overview for the clinician. Clin Med Insights Cardiol. 2019, 13:1179546819866445. 10.1177\/1179546819866445","journal-title":"Clin Med Insights Cardiol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2018.00009","article-title":"Cardiotoxicity of anticancer therapeutics","volume":"5","author":"Dong J","year":"2018","unstructured":"Dong J, Chen H. Cardiotoxicity of anticancer therapeutics. Front Cardiovasc Med. 2018, 5:9. 10.3389\/fcvm.2018.00009","journal-title":"Front Cardiovasc Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2016.04.008","article-title":"Shared risk factors for cardiovascular disease and cancer: implications for preventive health and clinical care in oncology patients","volume":"32","author":"Johnson CB","year":"2016","unstructured":"Johnson CB, Davis MK, Law A, Sulpher J. Shared risk factors for cardiovascular disease and cancer: implications for preventive health and clinical care in oncology patients. Can J Cardiol. 2016, 32:900-7. 10.1016\/j.cjca.2016.04.008","journal-title":"Can J Cardiol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-019-0796-0","article-title":"Cardiovascular disease and cancer: is there increasing overlap?","volume":"21","author":"Vincent L","year":"2019","unstructured":"Vincent L, Leedy D, Masri SC, Cheng RK. Cardiovascular disease and cancer: is there increasing overlap?. Curr Oncol Rep. 2019, 21:47. 10.1007\/s11912-019-0796-0","journal-title":"Curr Oncol Rep"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano JL","year":"2016","unstructured":"Zamorano JL, Lancellotti P, Rodriguez Mu\u00f1oz D, et al.. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016, 37:2768-801. 10.1093\/eurheartj\/ehw211","journal-title":"Eur Heart J"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s00508-022-02031-0","article-title":"Cardio-oncology in Austria: cardiotoxicity and surveillance of anti-cancer therapies: position paper of the Heart Failure Working Group of the Austrian Society of Cardiology","volume":"134","author":"Bergler-Klein J","year":"2022","unstructured":"Bergler-Klein J, Rainer PP, Wallner M, et al.. Cardio-oncology in Austria: cardiotoxicity and surveillance of anti-cancer therapies: position paper of the Heart Failure Working Group of the Austrian Society of Cardiology. Wien Klin Wochenschr. 2022, 134:654-74. 10.1007\/s00508-022-02031-0","journal-title":"Wien Klin Wochenschr"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2009.04.011","article-title":"Trastuzumab-induced cardiomyopathy: not as benign as it looks? A retrospective study","volume":"15","author":"Guglin M","year":"2009","unstructured":"Guglin M, Hartlage G, Reynolds C, Chen R, Patel V. Trastuzumab-induced cardiomyopathy: not as benign as it looks? A retrospective study. J Card Fail. 2009, 15:651-7. 10.1016\/j.cardfail.2009.04.011","journal-title":"J Card Fail"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21341","article-title":"Cardiotoxicity of anticancer treatments: epidemiology, detection, and management","volume":"66","author":"Curigliano G","year":"2016","unstructured":"Curigliano G, Cardinale D, Dent S, Criscitiello C, Aseyev O, Lenihan D, Cipolla CM. Cardiotoxicity of anticancer treatments: epidemiology, detection, and management. CA Cancer J Clin. 2016, 66:309-25. 10.3322\/caac.21341","journal-title":"CA Cancer J Clin"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa006","article-title":"Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry","volume":"41","author":"L\u00f3pez-Send\u00f3n J","year":"2020","unstructured":"L\u00f3pez-Send\u00f3n J, \u00c1lvarez-Ortega C, Zamora Au\u00f1on P, et al.. Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. Eur Heart J. 2020, 41:1720-9. 10.1093\/eurheartj\/ehaa006","journal-title":"Eur Heart J"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2016.01.027","article-title":"Mechanisms of cardiotoxicity of cancer chemotherapeutic agents: cardiomyopathy and beyond","volume":"32","author":"Moudgil R","year":"2016","unstructured":"Moudgil R, Yeh ET. Mechanisms of cardiotoxicity of cancer chemotherapeutic agents: cardiomyopathy and beyond. Can J Cardiol. 2016, 32:863-870.e5. 10.1016\/j.cjca.2016.01.027","journal-title":"Can J Cardiol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.5935\/abc.20190204","article-title":"Updated cardiovascular prevention guideline of the Brazilian Society of Cardiology - 2019","volume":"113","author":"Pr\u00e9coma DB","year":"2019","unstructured":"Pr\u00e9coma DB, Oliveira GM, Sim\u00e3o AF, et al.. Updated cardiovascular prevention guideline of the Brazilian Society of Cardiology - 2019. Arq Bras Cardiol. 2019, 113:787-891. 10.5935\/abc.20190204","journal-title":"Arq Bras Cardiol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2015.09.009","article-title":"Prevalence of preexisting cardiovascular disease in patients with different types of cancer: the unmet need for onco-cardiology","volume":"91","author":"Al-Kindi SG","year":"2016","unstructured":"Al-Kindi SG, Oliveira GH. Prevalence of preexisting cardiovascular disease in patients with different types of cancer: the unmet need for onco-cardiology. Mayo Clin Proc. 2016, 91:81-3. 10.1016\/j.mayocp.2015.09.009","journal-title":"Mayo Clin Proc"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.repc.2021.07.014","article-title":"Clinical experience of a cardio-oncology consultation at a tertiary university hospital in Portugal: an observational study","volume":"41","author":"Fiuza M","year":"2022","unstructured":"Fiuza M, Magalh\u00e3es A, Nobre Menezes M, et al.. Clinical experience of a cardio-oncology consultation at a tertiary university hospital in Portugal: an observational study. Rev Port Cardiol. 2022, 41:979-84. 10.1016\/j.repc.2021.07.014","journal-title":"Rev Port Cardiol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.01.002","article-title":"Hypertension in long-term survivors of childhood cancer: a nested case-control study","volume":"46","author":"Cardous-Ubbink MC","year":"2010","unstructured":"Cardous-Ubbink MC, Geenen MM, Schade KJ, Heinen RC, Caron HN, Kremer LC, Van Leeuwen FE. Hypertension in long-term survivors of childhood cancer: a nested case-control study. Eur J Cancer. 2010, 46:782-90. 10.1016\/j.ejca.2010.01.002","journal-title":"Eur J Cancer"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s40959-019-0054-5","article-title":"Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors","volume":"5","author":"Bansal N","year":"2019","unstructured":"Bansal N, Adams MJ, Ganatra S, et al.. Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors. Cardiooncology. 2019, 5:18. 10.1186\/s40959-019-0054-5","journal-title":"Cardiooncology"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.48.7884","article-title":"Trastuzumab-related cardiotoxicity among older patients with breast cancer","volume":"31","author":"Chavez-MacGregor M","year":"2013","unstructured":"Chavez-MacGregor M, Zhang N, Buchholz TA, et al.. Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol. 2013, 31:4222-8. 10.1200\/JCO.2013.48.7884","journal-title":"J Clin Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-020-01471-8","article-title":"Brazilian cardio-oncology: the 10-year experience of the Instituto do Cancer do Estado de Sao Paulo","volume":"20","author":"Costa IB","year":"2020","unstructured":"Costa IB, Bittar CS, Fonseca SM, et al.. Brazilian cardio-oncology: the 10-year experience of the Instituto do Cancer do Estado de Sao Paulo. BMC Cardiovasc Disord. 2020, 20:206. 10.1186\/s12872-020-01471-8","journal-title":"BMC Cardiovasc Disord"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2019.04.01","article-title":"Tobacco smoking after diagnosis of cancer: clinical aspects","volume":"8","author":"Jassem J","year":"2019","unstructured":"Jassem J. Tobacco smoking after diagnosis of cancer: clinical aspects. Transl Lung Cancer Res. 2019, 8:S50-8. 10.21037\/tlcr.2019.04.01","journal-title":"Transl Lung Cancer Res"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.4.1544","article-title":"Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience","volume":"15","author":"Krischer JP","year":"1997","unstructured":"Krischer JP, Epstein S, Cuthbertson DD, Goorin AM, Epstein ML, Lipshultz SE. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol. 1997, 15:1544-52. 10.1200\/JCO.1997.15.4.1544","journal-title":"J Clin Oncol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-91-5-710","article-title":"Risk factors for doxorubicin-induced congestive heart failure","volume":"91","author":"Von Hoff DD","year":"1979","unstructured":"Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, Muggia FM. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979, 91:710-7. 10.7326\/0003-4819-91-5-710","journal-title":"Ann Intern Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000005195","article-title":"Risk factors of trastuzumab-induced cardiotoxicity in breast cancer. A meta-analysis","volume":"95","author":"Jawa Z","year":"2016","unstructured":"Jawa Z, Perez RM, Garlie L, et al.. Risk factors of trastuzumab-induced cardiotoxicity in breast cancer. A meta-analysis. Medicine (Baltimore). 2016, 95:e5195. 10.1097\/MD.0000000000005195","journal-title":"Medicine (Baltimore)"},{"key":"ref25","article-title":"Cardiotoxicity of chemotherapy and targeted agents","volume":"11","author":"Mudd TW Jr","year":"2021","unstructured":"Mudd TW Jr, Khalid M, Guddati AK. Cardiotoxicity of chemotherapy and targeted agents. Am J Cancer Res. 2021, 11:1132-47.","journal-title":"Am J Cancer Res"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9061810","article-title":"Oncology and cardiac rehabilitation: an underrated relationship","volume":"9","author":"Venturini E","year":"2020","unstructured":"Venturini E, Iannuzzo G, D'Andrea A, et al.. Oncology and cardiac rehabilitation: an underrated relationship. J Clin Med. 2020, 9:10.3390\/jcm9061810","journal-title":"J Clin Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.15420\/ecr.2015.10.01.19","article-title":"Chemotherapy-related cardiomyopathy","volume":"10","author":"Piper SE","year":"2015","unstructured":"Piper SE, McDonagh TA. Chemotherapy-related cardiomyopathy. Eur Cardiol. 2015, 10:19-24. 10.15420\/ecr.2015.10.01.19","journal-title":"Eur Cardiol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/eci.12589","article-title":"Update on cardiotoxicity of anti-cancer treatments","volume":"46","author":"Rosa GM","year":"2016","unstructured":"Rosa GM, Gigli L, Tagliasacchi MI, et al.. Update on cardiotoxicity of anti-cancer treatments. Eur J Clin Invest. 2016, 46:264-84. 10.1111\/eci.12589","journal-title":"Eur J Clin Invest"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.04.030","article-title":"Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis","volume":"49","author":"Kalam K","year":"2013","unstructured":"Kalam K, Marwick TH. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis. Eur J Cancer. 2013, 49:2900-9. 10.1016\/j.ejca.2013.04.030","journal-title":"Eur J Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/164568-cancer-therapy-related-cardiotoxicity-a-comprehensive-retrospective-analysis-at-najran-cancer-center-saudi-arabia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:00:55Z","timestamp":1707508855000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/164568-cancer-therapy-related-cardiotoxicity-a-comprehensive-retrospective-analysis-at-najran-cancer-center-saudi-arabia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,2]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.41287","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,2]]}}}